https://weekly.chinacdc.cn/en/article/doi/10.46234/ccdcw2022.215

Landing Med, a Chinese medtech company focused on early cancer detection, has achieved a significant milestone by completing over 10 million cervical cancer screenings using artificial intelligence (AI). Established by Dr. Xiaorong Sun, the company has been integrating automation, digital, AI, and cloud computing technologies into Pap smear testing across China since 2017.

“I started Landing Med to address the challenge of a severe lack of pathologists and uneven distribution of health resources in China. As a female health tech entrepreneur, I strongly believe that women’s health is society’s health. We’re not just on a mission to save a woman’s life but to protect the well-being of her entire family,” says Dr. Xiaorong Sun, Founder and Chairwoman of Landing Med.

The Pap smear, a crucial preventive measure against cervical cancer, has faced global challenges due to the scarcity of pathologists, especially in low and middle-income nations. Conventional methods involving manual cell review under microscopes are labor-intensive and limit the productivity of cytopathologists. Landing Med’s AI-enhanced approach has revolutionized this process by significantly reducing the time required for review and increasing the scalability of Pap smear testing.